On August 7, 2025, Eton Pharmaceuticals, Inc. released its financial results for Q2 2025, highlighting Adjusted EBITDA as a key performance measure to assist investors in evaluating operational performance. The filing emphasizes the importance of this measure alongside standard GAAP results to provide a clearer view of the company's financial health.